Skip to main content

Table 1 Clinical features of tumors, immunohistochemistry of tru-cut core biopsies before chemotherapy, and reverse-transcriptase-mediated polymerase chain reaction (RT-PCR) after chemotherapy

From: Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy

  

Number of

     

c494

   

MDR1

Histology

Size

invaded nodes

erb

p53

Ki67 (%)

ER

PR

MDR1

LRP

Chemotherapy

Response

(RT-PCR)

Lobular

8.0

32

0

0

30

0

0

  

FAC4

SD

0

Ductal

7.0

31

1

1

60

0

0

  

Ttere-ADM4

PR

1

Ductal

6.0

21

1

1

30

1

1

 

1

FAC4

PR

1

Ductal

3.5 (T4b)

20

1

0

5

0

0

0

1

FAC3

PR

1

Ductal

6.0

20

0

0

35

0

0

1

1

FAC4

SD

1

Lobular

7.0

18

0

0

20

1

1

  

FAC4

PR

0

Ductal

3 (T4b)

16

0

0

30

1

1

0

1

FAC4

PR

1

Ductal

Diffuse

15

0

0

20

0

0

  

FAC4

PR

0

Lobular

Diffuse

11

0

0

80

1

1

1

1

FAC6

PR

1

Ductal

2.2 (T4b)

10

0

1

30

0

0

0

1

FAC4

PR

0

Ductal

7.0

10

0

0

35

1

0

1

1

FAC4

PR

1

Ductal

3 (T4b)

10

1

1

20

1

1

  

FAC4

PR

Failed

Ductal

5.0

9

1

0

20

0

0

  

FAC4

SD

Failed

Ductal

2.2+1.3

9

1

0

50

1

1

0

1

FAC4

PR

1

Ductal

4.0 (T4b)

8

1

1

 

1

1

  

FAC4

PR

0

Lobular

3.0

8

0

0

2

1

1

 

0

FAC4

SD

0

Ductal

Diffuse

7

1

0

20

1

0

 

1

FAC4

SD

1

Ductal

8.0

7

1

1

50

0

0

1

1

FAC4

CCR

1

Ductal

5.0 (T4b)

5

0

0

5

0

0

  

FAC3

PR

0

Ductal

Diffuse

4

0

0

50

1

0

 

1

FAC4

PR

1

Ductal

10.0

3

0

0

80

0

0

1

 

FAC3

PR

Failed

Ductal

6.0

3

1

0

40

0

0

 

1

FAC4

SD

0

Ductal

4.5 (T4b)

2

0

0

30

1

1

  

FAC6

SD

1

Ductal

2.5

2

0

0

no

0

0

  

FAC4

PR

Failed

Ductal

10.0

2

0

1

60

0

0

  

FAC4

CCR

1

Ductal

4.5+2.0

2

0

0

25

1

1

0

0

CMF4

PR

0

Ductal

5.0

2

1

1

40

1

0

0

 

FAC4

PR

0

Ductal

3.5

2

0

0

15

1

1

0

1

FAC4

SD

0

Ductal

3.0

2

0

1

35

0

0

 

1

FAC4

SD

0

Ductal

2.0

2

0

0

30

1

0

 

1

FAC4

PR

1

Ductal

2.6+2.3

1

0

0

40

1

1

  

FAC3

PR

1

Ductal

3.5

1

0

0

15

1

1

1

1

FAC4

PR

1

Undiff.

6.0

1

0

1

45

0

0

  

FAC6

SD

1

Lobular

6.0

1

0

0

10

1

1

0

0

FAC4

PR

0

Ductal

3.0

1

0

1

70

0

0

1

1

FAC2

PR

1

Ductal

5+2

0

1

1

20

0

1

  

FAC3

PR

Failed

Ductal

3.5

0

1

0

12

0

0

0

0

FAC3

PR

0

Ductal

10.0

0

0

1

15

0

0

  

FAC5

SD

0

Ductal

6.0

0

0

1

15

1

1

  

FAC4

PR

1

Lobular

5.0

0

0

0

10

1

1

1

0

FAC4

PR

0

Ductal

5.0

0

0

0

10

1

1

  

FAC4

PR

0

Ductal

4.0

0

0

0

10

0

0

0

0

FAC4

PR

0

Ductal

5.0

0

0

0

10

1

1

0

1

FAC4

PR

ND

Ductal

6.0

0

1

1

25

1

1

  

FAC4

PR

1

Ductal

2.0 (T4a)

0

1

1

30

1

1

  

FAC4

SD

0

Ductal

5.0

0

0

0

25

1

0

0

0

FAC4

PR

0

Ductal

5.0

0

0

0

15

1

1

0

0

FAC4

PR

0

Ductal

6.0

0

0

1

80

0

0

0

1

FAC4

PR

1

Ductal

3.6

0

0

0

10

1

1

1

1

FAC4

SD

0

Ductal

3.5

0

0

1

15

0

0

 

1

FAC4

PR

1

Ductal

4.0

0

0

0

20

1

0

 

1

FAC4

PR

0

Ductal

5.0

0

0

0

10

1

1

 

1

FAC4

PR

0

  1. Responses: 1, positive, 0, negative. Positivity levels: MDR1 (c494), only membrane staining in more than 10% of tumor cells; LRP, more than 20% reactive cells (for details, see the text). CCR, complete clinical response; PR, partial response; SD, stable disease; F, 5-fluorouracyl; A, doxorubicin (adriamycin); C, cyclophosphamide; M, methotrexate; undiff, undifferentiated; ND, not done; Ttere, taxotere.